Skip To Main Content
Jinlong Yin on Muck Rack

Jinlong Yin

As seen in: Wiley Online Library, MDPI, Science Magazine, BioRxiv, Cell Reports Physical Science, Cell Press, Canadian Journal of Infectious Diseases & Medical Microbiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jinlong

Contact Jinlong, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Spatiotemporal-switchable 2D NIR-II single-atom nanozyme for single-cell–level surgical navigation and glioblastoma phototherapy

|
By Zhao Li, Ziyi Zhou, Lyandysha Zholudeva, Ping Shangguan, Yong Zhong, Haigang Wu, Yisheng Liu, Gaoyang Wang, Cai Qi, Jiang Ouyang, Senfeng Zhao, Xin Wang, Jinlong Yin, Xiaoyuan Ji, Feng Bai, Kelong Fan, Jiefei Wang, Wei Tao, Bingyang Shi
| Science Magazine Verified
Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary The treatment of glioblastoma (GBM) is constrained by limitations in surgical precision during resection and limited spatial sensitivity of clinical imaging techniques. Here, Shangguan et al.
Open in Who Shared Issue with article?

Synthesis of selective BCL-XL PROTAC and potent antitumor activity in glioblastoma

|
By Meichen Liu, Biao Sun, Rui Niu, Yue Zhang, Xinyu Li, Jiefei Wang, Xin Wang, Jinlong Yin
| Cell Reports Physical Science Verified
Keywords glioblastoma glioblastoma stem cells proteolysis-targeting chimeras BCL-XL Introduction Glioblastoma (GBM), characterized as a rapidly growing and highly invasive malignancy, represents the most prevalent and lethal primary brain tumor, with a median survival of merely 14 months and a 2-year survival rate below 10%.1,2 Currently, the standard treatment regimen for GBM encompasses surgical resection, followed by radiation therapy and adjuvant temozolomide chemotherapy.3 Despite these...
Open in Who Shared Issue with article?

PVD Coatings for Lightweight Bipolar Plates

|
By Liam Cooper, Shicai Yang, Jinlong Yin, Parnia Navabpour
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 11 licensed articles (12 Total)